
Abeona Therapeutics, a NYC-based medical organization, develops gene therapies for deadly childhood diseases and manufactures next-gen AAV capsids.
Abeona Therapeutics, founded in New York City, focuses on developing gene therapies for severe childhood diseases, including Sanfilippo Syndrome Types A and B. The company leverages its expertise in manufacturing, delivery, development, and discovery of novel gene and cell therapies. Abeona's robust pipeline includes advanced AAV capsids and therapies such as prademagene zamikeracel for RDEB and ABO-50X for genetic eye disorders. Their fully operational manufacturing facility supports both preclinical and clinical studies.
Notable affiliated individuals include scientific advisors and researchers specializing in gene therapy. Abeona has attracted significant investment from biotech-focused venture capital firms. Key achievements include the submission of a Biologics License Application (BLA) for prademagene zamikeracel and advancements in their genetic eye disorder treatments. Abeona's impact is marked by its innovative approach to addressing unmet medical needs in pediatric genetic disorders, positioning it as a leader in the gene therapy space.

Apertura Gene Therapy
aperturagtx.com

Agtc
beacontx.com

Atsena Therapeutics
atsenatx.com

Akebia Therapeutics
akebia.com

bluebird bio
bluebirdbio.com

Aavogen
aavogen.com

Affinia Therapeutics
affiniatx.com

Regenxbio
regenxbio.com

Frontera Therapeutics

Kate Therapeutics

NabGen
nabgen.com

Capsida Biotherapeutics
capsida.com

Taysha Gene Therapies
tayshagtx.com

Locanabio

Astria Therapeutics
astriatx.com
Companies similar to Abeona Therapeutics include Apertura Gene Therapy, Agtc, Atsena Therapeutics and Akebia Therapeutics.
Abeona Therapeutics was founded in 1989.
Abeona Therapeutics' headquarters is located in New York City, NY, US.
Abeona Therapeutics' most recent funding round was for $20M (USD) in January 2024.
As of Jan 8, 2024, Abeona Therapeutics has raised a total of $354.7M (USD).
Abeona Therapeutics has 95 employees as of Feb 6, 2024.